Join our daily newsletter At The Bell to receive exclusive market insights
- Botanix Pharmaceuticals (BOT) shares its half yearly report and highlights its dermatology program advancements
- The company incurred a net loss after income tax of $6,508,794 because of the continued advancement of its dermatology and antimicrobial clinical pipeline
- During the half, Botanix spent $4.1 million in directs costs on its research and development program
- Botanix’s dermatology program is advancing, with canine atopic dermatitis (BTX 1204A) and rosacea (BTX 1702) programs on track to complete enrolments this quarter
- Its antimicrobial platform has also made progress with the completion of pre-clinical work
- Botanix Pharmaceuticals (BOT) last traded at 5.7 cents per share before the market opened on February 23
Botanix Pharmaceuticals (BOT) shares its half-yearly report and highlights its dermatology program advancements.
For the final half of 2021, the company incurred a net loss after income tax of $6,508,794 because of the continued advancement of its dermatology and antimicrobial clinical pipeline which has delivered strong results.
During the half, Botanix spent $4.1 million in directs costs on its research and development program.
Botanix continues to progress its pipeline of dermatology products focused on the treatment of serious skin diseases and identifying new solutions for bacterial infections.
Botanix’s dermatology program is advancing, with canine atopic dermatitis (BTX 1204A) and rosacea (BTX 1702) programs on track to complete enrolments this quarter and mid-2022, respectively.
Its antimicrobial platform has also made progress, with the completion of pre-clinical work to support the initiation of a Phase 2 human study in Australia during the next quarter.
The BTX 1702 program Phase 1b/2 clinical study in patients with moderate to severe papulopustular rosacea is progressing well and remains on track to complete patient enrolment in mid-year.
The eight-week study is active at 16 dermatology sites across Australia and New Zealand and will investigate the safety and tolerability of two different concentrations of BTX 1702.
As part of the study design, Botanix has centralised the review of each clinical investigator’s ratings for patient inclusion and is using advanced imaging technology across all sites to support clinical assessments.
The initiatives are expected to enhance the quality and consistency of the data collected, improving the probability of success.
If proven successful, then Botanix will initiate a Phase 2/3 clinical study in late CY2022.
Botanix Pharmaceuticals (BOT) last traded at 5.7 cents per share before the market opened on February 23.
